Structure Therapeutics Inc. ADR (GPCR): Price and Financial Metrics

Structure Therapeutics Inc. ADR (GPCR): $48.58

0.41 (+0.85%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

GPCR Price/Volume Stats

Current price $48.58 52-week high $75.02
Prev. close $48.17 52-week low $25.57
Day low $47.13 Volume 784,504
Day high $49.91 Avg. volume 780,582
50-day MA $40.92 Dividend yield N/A
200-day MA $45.59 Market Cap 2.26B

GPCR Stock Price Chart Interactive Chart >



GPCR Latest News Stream


Event/Time News Detail
Loading, please wait...

GPCR Latest Social Stream


Loading social stream, please wait...

View Full GPCR Social Stream

Latest GPCR News From Around the Web

Below are the latest news stories about STRUCTURE THERAPEUTICS INC that investors may wish to consider to help them evaluate GPCR as an investment opportunity.

Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now

It has genuine struggles ahead, but it has some actual value in hand as well.

Yahoo | December 25, 2023

7 Small-Cap Stocks That Wall Street Loves for Good Reason 

The market rally is showing signs of broadening to include small-cap stocks, here are seven that analysts are upgrading

Chris Markoch on InvestorPlace | December 22, 2023

7 Small-Cap Stocks That Wall Street Loves for Good Reason

As we head into 2024, it’s common for investors to look back on 2023. Much of this year had investors in a defensive posture. Small-cap stocks lagged sharply behind the broader market. However, the market rally that started in November is showing signs of broadening to include small-cap stocks. But which ones are ready to shine in 2024? One place for you to start your research is in the stocks that are receiving upgrades from analysts. The market is forward-looking, and analysts are a significan

Yahoo | December 22, 2023

Structure Plummets 43% After Trailing Lilly In Obesity Treatment

Structure's potential rival to Lilly in weight-loss drugs missed expectations on Monday, and GPCR stock took an absolute beating.

Yahoo | December 18, 2023

Another Drugmaker Hits Rocks Seeking a Weight-Loss Pill

Democratizing the [weight-loss drug revolution](https://www.wsj.com/articles/weight-loss-drug-ozempic-gold-rush-baf849bd) is proving harder than anticipated—and costing companies on Wall Street. Biotech Structure Therapeutics on Monday released disappointing study data for its weight-loss pill GSBR-1290, sending its U.

Yahoo | December 18, 2023

Read More 'GPCR' Stories Here

GPCR Price Returns

1-mo 34.38%
3-mo 33.17%
6-mo 47.26%
1-year 51.91%
3-year N/A
5-year N/A
YTD 19.19%
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!